HPE (Protego-PD)

About Plakous Therapeutics

Plakous Therapeutics is a private, pre-clinical stage biotech developing a novel biologic derived from the human placenta. Its lead asset, Human Placental Extract (HPE), is being investigated for its anti-inflammatory and pro-regenerative properties, with an initial focus on severe pediatric gastrointestinal conditions like necrotizing enterocolitis (NEC). The company has secured key regulatory designations (Orphan Drug, Rare Pediatric Disease) and significant non-dilutive funding from the NIH, positioning it to advance its first candidate into clinical trials. Its long-term vision is to become a leader in birth tissue-derived therapeutics for a range of inflammatory diseases.

Therapeutic Areas

Other Prevention of Necrotizing Enterocolitis (NEC) Drugs